Get informed when a big investor buys or sells
+ FollowUndervalued by 40964.4% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $143,568.00 |
|---|---|
| Enterprise Value | $-9,364,984.00 |
| Earnings per Share | $-2.14 |
| Beta | 1.61 |
| Outstanding Shares | 15,951,949 |
| P/E Ratio | -0.28 |
|---|---|
| PEG | 0.28 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.16 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | -0.17 |
| Debt to Equity | 0.05 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.